C
Causeway Therapeutics
Biotech & Life Sciences · Glasgow, United Kingdom · Founded 2015
MicroRNA therapies for repairing chronic tendon injuries MoreLess
Causeway Therapeutics is a clinical-stage biotechnology company spun out from the University of Glasgow in 2015. The company was co-founded by Dr. Derek Gilchrist, Mr. Neal Millar, and Professor Iain McInnes. The founders' journey began in a University of Glasgow laboratory where Dr. Gilchrist and Mr. Millar discovered that a specific microRNA, miR-29a, is a critical regulator of collagen production, the proteins that provide strength to tendons. They found that a loss of this molecule is a key factor in the development of tendinopathy, a condition of chronic tendon injury.
The company's core focus is on developing microRNA-based therapies to treat musculoskeletal diseases, particularly tendinopathies, which affect one in ten people and currently have no approved specific therapies. Causeway's lead product is TenoMiR®, a synthetic mimic of miR-29a designed to be injected directly into the damaged tendon. This treatment aims to restore the natural cellular processes, repair tendon structure, reduce pain, and restore function. The company is conducting international Phase 2 clinical trials for TenoMiR® for lateral epicondylitis (tennis elbow). Beyond human health, the company is also developing an analogous therapy, EquiMiR™, for tendinopathy in horses.
Causeway Therapeutics operates on a biopharmaceutical business model, focusing on the research and development of its proprietary therapies with the goal of bringing them to market. Its revenue generation will depend on the successful commercialization of its products following clinical trials and regulatory approval. The company has successfully raised significant capital to fund its clinical trials, including a £1M seed round in 2017 and an £8.75M investment in 2023 to advance its Phase 2 trial. Key investors include Mediqventures, Scottish Enterprise, and the University of Glasgow.
Keywords: microRNA therapy, tendinopathy, TenoMiR, tendon repair, musculoskeletal diseases, regenerative medicine, biotechnology, clinical trials, collagen regulation, miR-29a, lateral epicondylitis, tennis elbow treatment, EquiMiR, veterinary medicine, drug development, University of Glasgow spin-out, life sciences, injectable therapies, tissue regeneration, sports injuries
Company overview
Causeway Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Glasgow, United Kingdom
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 71.0
Valuation & funding
Causeway Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2025 | $3M | $58M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Feb 2023 | $12M | $46M | Declan Doogan · Glasgow University Holdings · Scottish Enterprise Growth Investments · Mediqventures | ↗ |
| GRANT✓Other financing | Jan 2021 | — | — | Undisclosed | — |
| GRANT✓Other financing | Jun 2020 | $304K | — | Undisclosed | — |
| GRANT✓Other financing | Jul 2019 | $1.6M | — | Undisclosed | — |
| GRANT✓Other financing | May 2018 | Undisclosed | — | ||
| SEED✓Equity / VC | Aug 2017 | Mediqventure · Scottish Enterprise Growth Investments · Mediqventures | ↗ | ||
| SPINOUT✓Other financing | Jan 2015 | University of Glasgow | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 10 |
| 2025 | 11 |
| 2024 | 7 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 2 |
Growth signals
Causeway Therapeutics website traffic
Latest recorded traffic for Causeway Therapeutics is 770 monthly website visits, down 35.8% over the last three months. Causeway Therapeutics's team declined 9.1% over the past year.
Comparisons
Causeway Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Causeway Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Causeway Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Causeway Therapeutics has talent and traffic
team presence
In the news
Latest news about Causeway Therapeutics
Recent press, funding announcements, and product moves mentioning Causeway Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Causeway Therapeutics
An AI-synthesized read of the highest-engagement posts about Causeway Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Causeway Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.